News for CLDX Stock

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease Celldex Therapeutics to Present at Upcoming Investor Conferences Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases Celldex Therapeutics to Present at Upcoming Investor Conferences Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 Celldex Therapeutics to Present at Upcoming Investor Conferences Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria Celldex Therapeutics to Present at Jefferies Healthcare Conference Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock Celldex Therapeutics Announces Proposed Public Offering of Common Stock Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference Celldex Therapeutics Announces Pricing of Public Offering of Common Stock Celldex Therapeutics Announces Proposed Public Offering of Common Stock Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023 Celldex Therapeutics to Present at Cantor Global Healthcare Conference Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 Celldex Therapeutics to Present at Jefferies Healthcare Conference Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™ Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023 Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022 Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022 Celldex to Participate in Upcoming November Investor Conferences Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022 Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Celldex Announces Two New Appointments to its Board of Directors Celldex to Present at the 2022 Jefferies Global Healthcare Conference Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022 Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021 Celldex to Participate in Upcoming Investor Conferences Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021 Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock Celldex Therapeutics Announces Proposed Public Offering of Common Stock Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021 Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021 Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021 Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN) Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference Celldex Presents Data from Oncology Portfolio at SITC 2020 Celldex Provides Corporate Update and Reports Third Quarter 2020 Results Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria Celldex Therapeutics to Present at Upcoming Healthcare Conferences Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020 Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Celldex Therapeutics Announces Proposed Public Offering of Common Stock Celldex Provides Corporate Update and Reports First Quarter 2020 Results Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call